Track LLY in your personal workspace
Monitor performance, SPY relative strength
and WOI View from your watchlist.
Alert me when LLY price is:
52W Range Position
98%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-07-29 12:57 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 1235.56. Holding above 1137.33 keeps the current thesis intact.
⚖️
✓
Fundamentals
Strong / Strong
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
1137.33
↗
Break Above
Confirmation improves above resistance.
1235.56
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 1137.33
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
20
$
Debt Financing
HIGH
LLY debt financing update
On May 20, 2026, Eli Lilly and Company (the “Company”) completed its offering of $750,000,000 aggregate principal amount of its Floating Rate Notes due 2028 (the “2028 Floating Rate Notes”), $500,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the “2029 Floating Rate Notes” and, together with...
On May 20, 2026, Eli Lilly and Company (the “Company”) completed its offering of $750,000,000 aggregate principal amount of its Floating Rate Notes due 2028 (the “2028 Floating Rate Notes”), $500,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the “2029 Floating Rate Notes” and, together with the 2028 Floating Rate Notes, the “Floating Rate Notes”), $750,000,000 aggregate principal amount of its 4.150% Notes due 2029 (the “2029 Notes”), $1,500,000,000 aggregate principal amount of its 4.375% Notes due 2031 (the “2031 Notes”), $1,250,000,000 aggregate principal amount of its 4.650% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of its 4.850% Notes due 2036 (the “2036 Notes”), $1,750,000,000 aggregate principal amount of its 5.600% Notes due 2056 (the “2056 Notes”) and $1,000,000,000 aggregate principal amount of its 5.700% Notes due 2066 (the “2066 Notes” and, collectively with the 2029 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2056 Notes, the “Fixed Rate Notes,” and together with the Floating Rate Notes, the “Notes”).
8-K Filing•SEC EDGAR
APR
30
●
Financial Results
HIGH
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2026 and provided updated 2026 financial guidance.
8-K Filing•SEC EDGAR
What's Driving LLY?
📈 Technical recovery is improving
Momentum is Neutral. Watch 1235.56 for confirmation and 1137.33 for structure risk.